What is the first line treatment for Cytomegalovirus (CMV)?

The first-line treatment for Cytomegalovirus (CMV) infection is ganciclovir or valganciclovir. These antiviral medications are specifically designed to target and inhibit the replication of the CMV virus. Ganciclovir is an analog of guanosine and works by interfering with viral DNA synthesis, which is vital for the virus's ability to reproduce and spread within the body. Valganciclovir is the oral prodrug form of ganciclovir, allowing for better bioavailability and convenience in administration.

In the case of CMV, particularly in immunocompromised patients, such as those with HIV/AIDS or those who have undergone organ transplantation, timely intervention with these antiviral agents is crucial to control the infection and prevent potential complications, including retinitis and systemic disease. The effectiveness of ganciclovir and valganciclovir in managing CMV infections makes them the standard treatment options in clinical practice for this particular virus.